Relief Therapeutics Holding (CHIX:RLFZ) Total Liabilities : CHF21.65 Mil (As of Jun. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Relief Therapeutics Holding Total Liabilities?

Relief Therapeutics Holding's Total Liabilities for the quarter that ended in Jun. 2024 was CHF21.65 Mil.

Relief Therapeutics Holding's quarterly Total Liabilities declined from Jun. 2023 (CHF31.41 Mil) to Dec. 2023 (CHF24.16 Mil) and declined from Dec. 2023 (CHF24.16 Mil) to Jun. 2024 (CHF21.65 Mil).

Relief Therapeutics Holding's annual Total Liabilities declined from Dec. 2021 (CHF70.09 Mil) to Dec. 2022 (CHF43.38 Mil) and declined from Dec. 2022 (CHF43.38 Mil) to Dec. 2023 (CHF24.16 Mil).

Relief Therapeutics Holding Total Liabilities Historical Data

The historical data trend for Relief Therapeutics Holding's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relief Therapeutics Holding Total Liabilities Chart

Relief Therapeutics Holding Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

5.57

11.00

70.09

43.38

24.16

Relief Therapeutics Holding Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Total Liabilities	Get a 7-Day Free Trial															60.41	43.38	31.41	24.16	21.65

Relief Therapeutics Holding Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Relief Therapeutics Holding's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	6.909	+	(2.095	+	6.203
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	7.366	+	1.589)
	=	24.16

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	76.39	-	52.228
	=	24.16

Relief Therapeutics Holding's Total Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	4.763	+	(2.019	+	6.465
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	7.335	+	1.072)
	=	21.65

Total Liabilities	=	Total Assets (Q: Jun. 2024 )	-	Total Equity (Q: Jun. 2024 )
	=	70.921	-	49.267
	=	21.65

Relief Therapeutics Holding Total Liabilities Related Terms

Thank you for viewing the detailed overview of Relief Therapeutics Holding's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Relief Therapeutics Holding Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relief Therapeutics Holding SA (CHIX:RLFz) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

RLFTY:USA RLFTF:USA 0QKQ:UK RLF:Switzerland

Address

Avenue de Secheron 15, Geneva, CHE, 1202

Website

https://www.relieftherapeutics.com

Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development such as RLF-TD011, and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast among others. Geographically the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.

Relief Therapeutics Holding Headlines

No Headlines